371 related articles for article (PubMed ID: 20979437)
21. Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas.
Takei H; Buckleair LW; Powell SZ
Neuropathology; 2008 Feb; 28(1):62-8. PubMed ID: 18021195
[TBL] [Abstract][Full Text] [Related]
22. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
24. Gonadotropin-releasing hormone (GnRH) and its receptor in human meningiomas.
Hirota Y; Tachibana O; Uchiyama N; Hayashi Y; Nakada M; Kita D; Watanabe T; Higashi R; Hamada J; Hayashi Y
Clin Neurol Neurosurg; 2009 Feb; 111(2):127-33. PubMed ID: 18980792
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study.
Loussouarn D; Brunon J; Avet-Loiseau H; Campone M; Mosnier JF
Hum Pathol; 2006 Apr; 37(4):415-21. PubMed ID: 16564915
[TBL] [Abstract][Full Text] [Related]
26. Expression of progestrone receptor and proliferative marker ki 67 in various grades of meningioma.
Shayanfar N; Mashayekh M; Mohammadpour M
Acta Med Iran; 2010; 48(3):142-7. PubMed ID: 21137648
[TBL] [Abstract][Full Text] [Related]
27. [Estrogen and progesterone receptors in meningiomas: immunohistochemical (Mib-1, p53) and clinico-morphological correlations].
Taddei GL; Caldarella A; Raspollini MR; Taddei A; Buccoliero AM
Pathologica; 2002 Feb; 94(1):10-5. PubMed ID: 11912872
[TBL] [Abstract][Full Text] [Related]
28. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
Korshunov AG; Shishkina LV; Golanov AV
Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
30. Expression of apoptotic and proliferation markers in meningiomas.
Konstantinidou AE; Pavlopoulos PM; Patsouris E; Kaklamanis L; Davaris P
J Pathol; 1998 Nov; 186(3):325-30. PubMed ID: 10211124
[TBL] [Abstract][Full Text] [Related]
31. The impact of progesterone receptor expression on relapse in the long-term clinical course of 93 benign meningiomas.
Strik HM; Strobelt I; Pietsch-Breitfeld B; Iglesias-Rozas JR; Will B; Meyermann R
In Vivo; 2002; 16(4):265-70. PubMed ID: 12224136
[TBL] [Abstract][Full Text] [Related]
32. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
33. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
34. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors.
Maiuri F; De Caro MB; Esposito F; Cappabianca P; Strazzullo V; Pettinato G; de Divitiis E
J Neurooncol; 2007 Mar; 82(1):63-8. PubMed ID: 17225937
[TBL] [Abstract][Full Text] [Related]
35. Primary resected meningiomas: relapses and proliferation markers.
Kalala JP; Caemaert J; De Ridder L
In Vivo; 2004; 18(4):411-6. PubMed ID: 15369177
[TBL] [Abstract][Full Text] [Related]
36. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
Abramovich CM; Prayson RA
Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
[TBL] [Abstract][Full Text] [Related]
37. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
39. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
Cobleigh MA; Tabesh B; Bitterman P; Baker J; Cronin M; Liu ML; Borchik R; Mosquera JM; Walker MG; Shak S
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8623-31. PubMed ID: 16361546
[TBL] [Abstract][Full Text] [Related]
40. Characterization of morphologically benign biologically aggressive meningiomas.
Rao S; Sadiya N; Doraiswami S; Prathiba D
Neurol India; 2009; 57(6):744-8. PubMed ID: 20139503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]